؉ subsets in bone marrow and peripheral blood after priming with glycosylated or non-glycosylated rhG-CSF Autologous stem cell support after high-dose chemotherapy has been improved by the use of peripheral blood progenitor and stem cells (PBSC) compared to the use of unprimed bone marrow cells, reducing morbidity and mortality by reducing the time to engraftment. CD34 + progenitors can be mobilized from the marrow environment by priming the patients with the myeloid growth factor rhG-CSF for 4 to 7 days and subsequently harvesting these cells by leukapheresis.
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The optimal priming procedure appears to be chemotherapy combined with the myeloid growth factor rhG-CSF. 2, 3 It is believed that the effects of G-CSF are an indirect result of expansion of the haematopoietic system. 4 Differences have been found in the peak levels of progenitor cells in healthy volunteers compared to patient groups after G-CSF treatment. Patients with haematological malignancies show substantial variation in the peak levels of progenitor cells, and these variations appear to depend mainly on the extent of previous chemo-or radiotherapy, known to damage marrow function by reducing the number of stem cells. 3 Several studies have shown both glycosylated and nonglycosylated rhG-CSF to be effective stem cell mobilisers in normal volunteers or donors. 5, 6 The two G-CSF products may have different biological in vivo effects due to the glycosylation, based on evidence from in vitro studies. 7, 8 It is questionable however, if such a difference is of clinical relevance.
We decided to perform a non-randomised pilot study with the primary aims of comparing the mobilisation capacity of glycosylated rhG-CSF (Granocyte; Lenograstim, Chugai-Rhône-Poulenc, Paris, France) and non-glycosylated (Neupogen; Filgrastim, Amgen, Thousand Oaks, CA, USA) rhG-CSF by daily enumeration of blood CD34 + progenitors, and to evaluate qualitative differences by multiparametric flow cytometry analysis of CD34 + subsets in bone marrow and leukapheresis products. The study was initiated in order to evaluate the need for a larger, randomised comparison of the two rhG-CSFs.
The patients included had lymphoid malignancies (ALL, non-Hodgkin's lymphoma or Hodgkin's disease) at the time of the study and were considered eligible for autologous stem cell transplantation. Ten patients were treated with Granocyte 10 g/kg given as a subcutaneous injection once daily for 5 days, and 33 patients were treated with Neupogen 10 g/kg in the same way. Three patients in the Granocyte group and 20 patients in the Neupogen group (30% vs 61%; P = 0.46 by Fisher's exact test) received high-dose cyclophosphamide, 4 g/m 2 8 days before growth factor treatment was initiated. The study design included daily enumeration of CD34 + cells in the blood followed by a comparison of blood progenitors in the leukapheresis product and bone marrow progenitors aspirated at the time of apheresis. 3, 9 Blood progenitor harvesting was performed using a CS3000 plus cell separator (Baxter, Deerfield, IL, USA). 3 The products were analysed in parallel and immunophenotyping of cell subsets was carried out in eight patients treated with Granocyte and 11 patients treated with Neupogen by flow cytometry using a FACScan equipped with an argon laser (Becton Dickinson, San Jose, CA, USA) in accordance with the Nordic protocol. 9 The committed lineage-specific late progenitors were analysed as CD34 + /CD33 + , CD13 + , CD14 + (myelo-monocytoid) subsets and CD61
+ , GlyA, CD71 + (megakaryocyte and erythroid) progenitors. B and T lymphoid progenitors were studied by analysis of CD34 + /CD10 + , CD19 + , CD2 + and CD7 + subsets ( Figure 1 ).
The two groups exhibited identical patient characteristics and no differences in the toxicity during rhG-CSF administration were observed. Evaluation of blood CD34
+ levels by flow cytometry did not reveal significant differences during the mobilisation. The likelihoods of reaching more than 20 000 CD34 + stem cells/ml blood and subsequently of obtaining an adequate harvest by leukapheresis were equal as were the number of nucleated cells and total number of CD34 + cells harvested. Neither did we find any differences when analysing the patients primed with growth factor alone. Finally, the lineage-specific CD34 + subsets (myeloid, megakaryocyte and erythroid) analysed by double staining did not show any major differences in either the leukapheresis product or the bone marrow (Figure 1 ). In the subsets of lymphoid progenitors however, a borderline significant difference was found in the leukapheresis product in subsets of CD19 + (median 2.5% in the Granocyte vs 1.0% in the Neupogen group) as well as CD7
+ cells (median 6% in the Granocyte vs 2% in the Neupogen group) (Figure 1 ).
In conclusion, we studied PBSC mobilisation and CD34 + subsets in bone marrow and leukapheresis product in a subgroup of patients by flow cytometry, in order to evaluate if the treatment with glycosylated G-CSF could induce any change in the stem cell subsets which theoretically could be of importance for engraftment. However, we found no differences in the two groups of patients examined, either in patients treated with G-CSF alone or in patients who received both chemotherapy and growth factor. In vitro studies have suggested that glycosylation induces a higher potency of the drug, but in our study there was no difference in the number of mobilised CD34 + cells in blood at any time, or in the number of CD34 + cells harvested by leukapheresis by equal doses of growth factors, either per patient or per kilogram bodyweight. It is of course possible that a smaller dose of G-CSF would prove equally efficient in achieving an adequate CD34 + harvest in many patients, but our study was not designed to answer this question. An equal number of patients in the two groups attained suf- 
ficient CD34
+ cells in peripheral blood for collection by leukapheresis. Our findings of maximum values for CD34 + cells are somewhat smaller than those found in the doseescalation study by Höglund et al 6 at their highest dosage of 10 g/kg, the same dose as used in the present study. The most likely explanation is that Höglund et al studied healthy individuals, and their observations cannot necessarily be expected in patients with haematological diseases. Our findings are in accordance with the preliminary results from a similar study, comparing mobilisation of stem cells with glycosylated and non-glycosylated G-CSF in patients with haematological malignancies or breast cancer. 10 We conclude that in comparison with non-glycosylated rhG-CSF, priming with glycosylated recombinant G-CSF at equal doses does not appear to affect the quantity or quality of the subsequently harvested CD34
+ stem cells in patients with lymphoid malignancies. As a consequence we find no reason to conduct further dose-escalating randomised trials.
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Treatment of patients with malignant lymphoma with Mini-BEAM reduces the yield of CD34 ؉ peripheral blood stem cells
It is currently unclear whether or not patients with malignant lymphoma who relapse after achieving a complete remission benefit from reinduction chemotherapy prior to mobilization of peripheral blood stem cells (PBSC) and high-dose chemotherapy (HDC). Previous phase II studies in patients with Hodgkin's Disease (HD) or non-Hodgkin's lymphoma (NHL) failed to show a survival advantage for patients in first relapse receiving reinduction chemotherapy before mobilization of PBSC compared to patients proceeding directly to mobilization of PBSC without an attempt to induce a second remission. 1,2 However, the numbers of patients in these studies were few and the potential selection biases great. Therefore, a randomized trial was designed to answer this question. A regimen of carmustine, etoposide, cytarabine and melphalan (Mini-BEAM) was selected for the reinduction arm because of proven efficacy as salvage therapy for patients with relapsed or refractory HD prior to HDC with autologous bone marrow (BM) support. 3, 4 At the first sign of relapse one group of patients was Leu9, Becton Dickinson randomized to receive immediate mobilization of PBSC with cyclophosphamide, etoposide and granulocyte colonystimulating factor (CE/G-CSF) followed by HDC with BEAC 1,2 and the other group received induction with Mini-BEAM and were scheduled to receive the same mobilization and HDC regimens. Fifteen patients were enrolled in this study; seven (six with NHL and one with HD) were randomized to receive Mini-BEAM and eight (six with NHL and two with HD) to receive immediate mobilization of PBSC. Seven patients received one (n = 2) or two (n = 5) cycles of Mini-BEAM at the following doses: carmustine 60 mg/m 2 on day 1, etoposide 75 mg/m 2 on days 2-5, cytarabine 100 mg/m 2 /twice a day on days 2-5 and melphalan 30 mg/m 2 on day 6.
3,4 Table 1 shows the yields of CD34 + cells from each group of patients following CE/G-CSF. None of the seven patients receiving Mini-BEAM achieved the target CD34 + cell dose of у2.5 × 10 6 /kg in a median of five aphereses. 5 Four of the seven patients who received Mini-BEAM underwent second attempts to mobilize PBSC (two with CEP/G-GCSF and two with G-CSF alone) with harvesting of a median of 0.15 × 10 6 (range 0.003-0.8) CD34 + cells/kg in a median of four (range 2-8) aphereses. Three of the seven patients who received Mini-BEAM ultimately received HDC with infusion of 1.57, 1.75 and 2.33 × 10 6 CD34 + cells/kg
